Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.49 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015120 | 1.00 | POLB (0.54) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL18058958 | 0.93 | POLB (0.53) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL23205583 | 0.92 | POLB (0.58) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL18886150 | 0.91 | POLB (0.51) | POLBENPP1P2RY1ADORA1 | |
| SCHEMBL25786818 | 0.91 | POLB (0.59) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL12015128 | 0.89 | POLB (0.50) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL14534398 | 0.89 | POLB (0.50) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL12087558 | 0.89 | POLB (0.50) | POLBENPP1P2RY1ADORA1P2RY2 | |
| SCHEMBL21447399 | 0.88 | POLB (0.56) | POLBENPP1P2RY1ADORA1 | |
| SCHEMBL17122136 | 0.88 | POLB (0.56) | POLBENPP1P2RY1P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023080225-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SPINOCEREBELLAR ATAXIA | 国立大学法人東京医科歯科大学 | 2023-05-11 | — | — | WO | disclosed |
| EP-2647713-B1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160002636-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| EP-2305805-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7906639-B2 | Oligonucleotides having a 2′-O,4′-C-ethylene nucleotide in the third position of the 3′-end | SANKYO COMPANY, LIMITED (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | POLB 35/4885ENPP1 450/4885P2RY1 4265/4885 |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | POLB 17/4885ENPP1 6/4885P2RY1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.